logo

Stock Screener

Forex Screener

Crypto Screener

ALC

Alcon Inc. (ALC)

$

74.08

+1.48 (2.00%)


Key metrics

Financial statements

Free cash flow per share

Free cash flow per share

3.2276

Market cap

Market cap

35.9 Billion

Price to sales ratio

Price to sales ratio

3.5804

Debt to equity

Debt to equity

0.2375

Current ratio

Current ratio

2.6015

Income quality

Income quality

1.9155

Average inventory

Average inventory

2.4 Billion

ROE

ROE

0.0493



Technology

Technology

Technology – consumer electronics

Largecap

Largecap

With a market cap of 121,78 bil stock is ranked 1

Low risk

Low risk

ISS score of this stock is ranked 1


Company description

Profile

The financial data pertains to the fiscal year 2024. During this period, the company incurred an income tax expense of $238,000,000.00 indicating its tax obligations. The net total of other income and expenses is -$157,000,000.00 reflecting non-core financial activities. Furthermore, the gross profit ratio is 0.56 reflecting the efficiency of the company's production and sales operations. The net income ratio is 0.10 reflecting the company's profitability margin. Alcon Inc. is dedicated to advancing eye care through its Surgical and Vision Care segments, offering a comprehensive range of products such as intraocular lenses, surgical equipment, diagnostic tools, contact lenses, and ocular health solutions. Founded in 1945 and headquartered in Geneva, Switzerland, Alcon is committed to innovation and quality, ensuring that healthcare professionals and patients benefit from its advanced technologies and eye care solutions. The stock is reasonably priced at $77.25 appealing to a broad range of investors. With a mid-range market capitalization of $36,625,152,000.00 the company is a steady performer. Additionally, the stock has an average trading volume of 2,125,182.00 indicating moderate liquidity. Alcon Inc. is a key player in the Medical - Instruments & Supplies industry, contributing significantly to the overall market landscape. It belongs to the Healthcare sector, driving innovation and growth. The company’s strategic focus on enhancing vision care and developing advanced surgical solutions positions it as a vital contributor in the eye care market, meeting the diverse needs of eye care professionals and patients worldwide.

What is Alcon Inc. (ALC)'s current stock price?

The current stock price of Alcon Inc. (ALC) is $73.99 as of 2025-10-15. Prices may fluctuate during the trading day. For real-time updates, check your brokerage platform or financial news websites.

Investing in Alcon Inc. (ALC) depends on multiple factors, including revenue growth, profit margins, debt-to-equity ratio, earnings per share, and return on equity. Analysts have rated it as B, with a Bullish outlook. Always conduct your own research before investing.

Analysts predict Alcon Inc. stock to fluctuate between $71.55 (low) and $99.20 (high) in the next 365 days, reflecting market expectations and potential volatility.

As of 2025-10-15, Alcon Inc.'s market cap is $36,625,152,000, based on 494,400,000 outstanding shares.

Compared to Meta Platforms, Inc. Class A Common Stock, Alcon Inc. has a Lower Market-Cap, indicating a difference in performance.

Alcon Inc. pays dividends. The current dividend yield is 0.36%, with a payout of $0.33 per share.

To buy Alcon Inc. (ALC) stock: Open a brokerage account (e.g., Robinhood, TD Ameritrade, E-Trade). Search for ALC. Place an order (Market, Limit, etc.).

The best time to invest depends on market trends and technical indicators, which show a Bullish trend based on economic conditions and company performance.

Revenue: $9,911,000,000 | EPS: $2.06 | Growth: 4.04%.

Visit https://www.alcon.com/investor-relations for detailed financial reports.

You can explore historical data from here

All-time high: $101.10 (2024-09-12) | All-time low: $55.21 (2022-10-13).

Key trends include market demand, economic conditions, interest rates, and industry competition, which influence the stock's performance.


News

ALC

businesswire.com

STAAR Surgical Board of Directors Reiterates Unanimous Recommendation that STAAR Stockholders Vote “FOR” the Alcon Merger Agreement on WHITE Proxy Card

LAKE FOREST, Calif.--(BUSINESS WIRE)--STAAR Surgical Company (NASDAQ: STAA) (“STAAR”), the global leader in phakic IOLs with the EVO family of Implantable Collamer® Lenses (EVO ICL™) for vision correction, today provided the following statement in response to a report issued by Glass, Lewis & Co., LLC (“Glass Lewis”) related to STAAR's pending merger with Alcon (SIX/NYSE: ALC): The STAAR Board of Directors and management team strongly disagree with the recommendation issued by Glass Lewis.

ALC

prnewswire.com

Defender Capital Opposes STAAR Surgical's Proposed Sale to Alcon

CHARLOTTE, N.C. , Oct. 7, 2025 /PRNewswire/ -- Defender Capital ("Defender" or "we"), a long-term shareholder of STAAR Surgical Company ("STAAR" or the "Company") (NASDAQ: STAA) owning approximately 1.5% of the Company's outstanding common stock, today issued the following statement outlining its opposition of the proposed acquisition of STAAR by Alcon Inc. ("Alcon") (NYSE: ALC): We have been significant STAAR shareholders for more than ten years and remain convicted in the significant value of the Company.

ALC

businesswire.com

STAAR Surgical: Independent Industry Analysts Recognize Merits of Alcon Merger, the Value It Provides, and the Downside Risks Facing STAAR on Standalone Basis

LAKE FOREST, Calif.--(BUSINESS WIRE)--STAAR Surgical Company (NASDAQ: STAA), the global leader in phakic IOLs with the EVO family of Implantable Collamer® Lenses (EVO ICL™) for vision correction, today highlighted commentary from numerous independent industry analysts who recognize that STAAR's merger with Alcon (SIX/NYSE: ALC) – and the compelling, certain, premium cash value it provides – is the best path forward for STAAR stockholders. Stephen Farrell, CEO of STAAR, said, “Prior to the Alcon.

ALC

globenewswire.com

Johnson Fistel Investigates Fairness of Proposed Sale of STAAR Surgical

SAN DIEGO, Oct. 03, 2025 (GLOBE NEWSWIRE) -- Shareholder rights law firm Johnson Fistel, PLLP continues its investigation into whether the board members of STAAR Surgical Company (NASDAQ: STAA) breached their fiduciary duties in connection with the proposed sale of the Company to Alcon (NYSE: ALC).

ALC

businesswire.com

Alcon and STAAR Surgical Announce Expiration of Hart-Scott-Rodino Waiting Period for Alcon's Acquisition of STAAR

GENEVA & LAKE FOREST, Calif.--(BUSINESS WIRE)--Alcon (SIX/NYSE: ALC), the global leader in eye care dedicated to helping people see brilliantly, and STAAR Surgical Company (NASDAQ: STAA) (“STAAR”), the manufacturer of the Implantable Collamer® Lens (ICL), today announced that the waiting period under the Hart-Scott-Rodino Antitrust Improvements Act of 1976, as amended (HSR), in connection with Alcon's acquisition of STAAR, expired at 11:59 p.m. ET on September 29, 2025. As previously announced,.

ALC

seekingalpha.com

Alcon: Seeing Is Believing As Buyout Of STAAR Surgical Hangs In Balance

Alcon Inc. gets upgraded to a Buy again after my prior hold rating. Upside could come from macro-level clinical demand in the eyecare niche, but also a diverse and growing product portfolio in both the consumer and surgical space. Operating cashflow growth is proven, although there is limited dividend growth history as the firm only went public in 2019 after its spinoff from Novartis.

ALC

businesswire.com

Algoma Central Corporation Celebrates 100th Vessel Milestone

ST. CATHARINES, Ontario--(BUSINESS WIRE)-- #yourmarinecarrierofchoice--Algoma Central Corporation (“Algoma” or “the Company”) (TSX:ALC), today took delivery of the Algoma Legacy, the first of three new methanol-ready Kamsarmax-sized ocean belt self-unloading vessels. With this addition, the Company will have an ownership interest in 100 vessels across its global fleet, a historic milestone that underscores its leadership in long-term growth in diversified short sea shipping markets. “This is a proud moment on two fronts: t.

ALC

businesswire.com

Yunqi Capital, 5.1% Holder and One of STAAR Surgical Company's Largest Shareholders, Announces Intention to Vote Against the Proposed Sale to Alcon

HONG KONG--(BUSINESS WIRE)--Yunqi Capital Limited (together with its affiliates and the funds it advises, “Yunqi Capital”), an investment management firm and 5.1% shareholder of STAAR Surgical Company (“STAAR”) (NASDAQ:STAA), today announced its opposition to the Company's proposed sale to Alcon Inc. (SIX/NYSE:ALC) on the terms announced on August 5, 2025. Yunqi Capital released the following open letter to fellow STAAR shareholders explaining why it opposes the transaction: September 22, 2025.

ALC

zacks.com

Is it a Prudent Move to Retain ALC Stock in Your Portfolio Now?

Alcon sees growth from surgical innovation and vision care products, but faces macro pressures and fierce competition.

ALC

zacks.com

Alcon's UNITY VCS Shows Superior Efficiency in Studies, Stock Up

ALC's UNITY VCS shows faster, more efficient cataract and vitreoretinal surgery results, lifting shares after study presentations.

See all news

logo
Stocks, Indicators, Pattern screeners all at one place
Stock Screener
Forex Screener
Crypto Screener